Everyone who will turn 65 in 2050 has already been born today — so an aging world isn't a guess, it's a demographic certainty that decides where money flows for the next 25 years. The global 65+ population is set to grow from ~830 million to 1.5 billion by 2050, and an aging body and life "need" things in a clear order — housing, drugs, devices, pensions, all the way to funerals. This lesson is the map that strings the 10 categories of the aging economy onto the single life path everyone walks (each category has its own deep-dive chapter).
Alzheimer's breakthrough and senior housing strength offset Social Security and Medicare funding worries
▼
Social Security and Medicare insolvency dates moved closer Social Security's insolvency accelerated to 2032, threatening about 22% benefit cuts, while Medicare's trust fund now depletes by 2033, risking Part A reimbursement reductions. Political deadlock and no reform plan add uncertainty.
This is the biggest new negative force for the aging population, directly threatening retiree income and healthcare funding.
▲
First Alzheimer's drug shows meaningful improvement The Cerezen device became the first to improve Alzheimer's in trials, with 78% of patients improving. This is a major medical breakthrough for a disease tied to aging.
It is a new positive development that could improve quality of life for millions and reduce long-term care burdens.
▲
Senior housing demand stayed strong Ventas raised guidance, Welltower's NOI grew 16.4%, and Alignment Healthcare beat earnings. This shows robust demand for senior housing and care services.
It highlights a key positive trend in the aging population sector, with real business results confirming demand.
◆
Retirement savings remain inadequate and policy responses vary Most 55–64 year-olds have $50,000 or less saved, and proposals like raising the retirement age to 70 would cut lifetime benefits. But higher rates boosted life insurers, and new policies in the U.S., China, and Quebec support elderly care.
It captures the mixed picture: ongoing savings shortfalls and potential benefit cuts, offset by some policy support and insurer gains.
Latest
▲3▼1
Social Security cuts loom, senior housing booms, drug access widens
▲
Senior housing demand and capital keep accelerating Target Healthcare REIT posted higher earnings, NAV and dividend cover, with inflation-linked rents and low debt. This confirms that senior housing demand and investment remain strong, pushing the theme up as an aging population needs more care homes and rental income rises.
Shows continued strength in senior housing, a core Aging Population sub-area.
▲
New drugs and devices expand treatment for aging diseases Axsome's Alzheimer's agitation drug hit record prescriptions, AbbVie won FDA approval for a new Parkinson's drug, and Orchestra BioMed completed enrollment in a hypertension device trial. These advances widen the patient pool and boost demand for chronic-disease pharma and medical devices.
Highlights new product approvals and trial progress that expand the market for aging-related treatments.
▲
Medicare GLP-1 coverage adds 700,000 seniors Eli Lilly said about 700,000 new seniors started GLP-1 treatment since Medicare began covering obesity drugs in July, with 70% using Lilly medicines. This expands the market for chronic-disease pharma and shows how policy can unlock demand from the aging population.
Demonstrates a major new demand driver from Medicare coverage for obesity drugs.
▼
Social Security insolvency accelerates to 2032 Trump's One Big Beautiful Bill Act moved Social Security insolvency up to 2032, with a possible 24% benefit cut. This threatens future retirement income, but also pushes retirees toward private annuities and longevity products, creating demand for retirement-income solutions.
A key policy shift that affects retirement income and annuity demand.
Q3 2026
▲2▼2
Senior housing and annuities boom, but retirement safety net weakens
▲
Senior housing demand hits record highs Senior housing occupancy reached a record 92.5%, rents rose, and REIT capital poured in. This shows strong demand for senior living and care services as the population ages.
It is the clearest new positive force for the aging theme this quarter.
▲
Record annuity sales and new treatments expand options Annuity sales hit a record $228.7 billion, and new Alzheimer's, Parkinson's, and GLP-1 treatments expanded care. 700,000 seniors gained Medicare obesity-drug coverage, improving health options.
It highlights new product and treatment growth supporting aging-related industries.
▼
Retirement savings fall short as Social Security worsens Median 401(k) balances cover only about three years of spending, and nearly half of private workers lack retirement accounts. Social Security insolvency moved up to 2032, risking up to 24% benefit cuts.
It captures the main new threat to retirement income security this quarter.
▼
Medicare changes raise costs and disrupt care Medicare Advantage disruption displaced millions, high denial rates cut provider volumes, and the end of a $9.8 billion Part D subsidy raised seniors' drug costs. Affordability pressures intensified.
It shows new policy-driven cost and access problems for seniors.
News & notes movingAging Population
United States
Medical Devices for the Aging Body▲
Tempus AI Wins FDA Clearance for Two AI-ECG Cardiac Products
Tempus AI has received 510(k) clearance from the Food and Drug Administration for two next-generation AI cardiovascular products, Tempus ECG-MR and Tempus ECG-PH. Tempus ECG-MR analyzes standard 12-lead resting electrocardiograms to detect signs associated with undiagnosed moderate or severe mitral regurgitation, while Tempus ECG-PH is an AI-enabled software device that analyzes standard 12-lead ECG data and provides a binary output for signs associated with pulmonary hypertension. The clearances come as the AI-ECG analysis market is expected to grow from $2.01 billion in 2025 to $2.40 billion in 2026, a compound annual growth rate of 19.3%, according to the Business Research report. Among peers, GE HealthCare's Advanced Imaging Solutions segment, which combines the former Imaging and AVS businesses, generated $3.77 billion in revenues in the second quarter of 2026, up 5.0% organically, with segment EBIT margin rising 90 basis points to 13.9%. iRhythm Holdings, whose platform is supported by more than 3 billion hours of curated ECG data and more than 12 million patient reports, expanded work with Desert Oasis Healthcare and signed two commercial agreements through Luum during the second quarter of 2026. Tempus shares have declined 17.7% over the past year, and the stock currently trades at a forward 12-month price-to-sales ratio of 7.30X versus an industry average of 4.82X.
Abbott Wins FDA Approval for CardioMEMS HF System Patient-Facing Updates
Abbott announced U.S. Food and Drug Administration approval for updates to its CardioMEMS HF System that, for the first time, let U.S. CardioMEMS patients view their pulmonary artery pressure readings directly on their smartphones through the new CardioGuide HF App. The new capabilities also include Dynamic Treatment Plan, a software feature that lets clinicians set up personalized medication adjustment plans based on changes in a patient's pulmonary artery pressure and send medication adjustment instructions directly to patients through the app. The CardioMEMS HF System, which measures pulmonary artery pressure through an implanted sensor in the pulmonary artery, has been shown to reduce heart failure hospitalizations and mortality risk, and clinicians have used its readings for more than a decade to identify signs of worsening heart failure and guide treatment. Abbott said it plans to make the CardioGuide HF App and Dynamic Treatment Plan available later this year. Katie Spayde, vice president of Abbott's heart failure division, said the new capabilities help patients stay informed, engaged and connected to their care between doctor visits.
Aging Population › Medical Devices for the Aging Body ▲Technology
ABT · Technology · Positive FDA approval of CardioGuide HF App and Dynamic Treatment Plan updates to Abbott's CardioMEMS HF System, a new product/tech development.
Novo Nordisk Targets Over $23 Billion in Pipeline Sales by 2035 as GLP-1 Competition Bites
Novo Nordisk is diversifying beyond its GLP-1 obesity and diabetes franchise, aiming to launch more than five potential blockbuster drugs by 2030 and generate over $23 billion in pipeline-related sales by 2035. The company, whose Ozempic and Wegovy have driven recent growth, has begun exploring the hair-loss market, which its Chief Scientific Officer says can leverage Novo's scientific knowledge, and plans to advance multiple Phase 3 programs across obesity, diabetes and other therapeutic areas. Chief Executive Mike Doustdar acknowledged the loss of confidence, saying it takes time and hard work to build back, after the company's post-Wegovy strategy presentation sent hair-loss drug developers Veradermics and Absci higher. Novo has lost ground to rival Lilly in the injectable GLP-1 market and faces key semaglutide patent expirations in major markets in the early 2030s, prompting Morgan Stanley to downgrade the stock to Sell on medium-term growth concerns. Novo trades at around 10.2x forward GAAP earnings, below its five-year average of 30.0x and the sector median of 23.3x, while its forward price-to-sales ratio of 3.8x is below its five-year average of 9.6x and broadly in line with the sector median of 3.7x.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▼Competition
Aging Population › Chronic-Disease Pharma Franchises ▼Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▼Competition
NVO · Competition · Negative Novo Nordisk has lost ground to rival Lilly in the injectable GLP-1 market and faces semaglutide patent expirations, prompting a Morgan Stanley downgrade.
LLY · Competition · Positive Novo Nordisk acknowledged losing ground to rival Lilly in the injectable GLP-1 market, a competitive gain for Lilly.
ABSI · Demand · Positive Absci shares rose after Novo Nordisk's strategy presentation highlighted the hair-loss market, signaling potential demand for hair-loss drug developers.
MANE · Demand · Positive Veradermics shares rose after Novo Nordisk's strategy presentation signaled interest in the hair-loss market, a potential demand driver for hair-loss drug developers.
Prismic Life Reinsures $5 Billion of Prudential Japanese Whole Life Reserves
Prismic Life Holding Company announced an agreement with Prudential Financial to reinsure approximately $5 billion of reserves backing USD-denominated Japanese whole life insurance policies originated by Prudential's Japanese affiliates. Prudential's obligations to policyholders remain unchanged and the company will continue to administer the contracts. The deal expands the existing relationship between the two firms, whose in-force and new business flow transactions now cover more than $22 billion of USD-denominated liabilities. Prismic chief executive Nandini Mongia called the transaction another important milestone in the company's growth journey, while Prudential chairman and chief executive Andy Sullivan said it reflects continued focus on disciplined capital allocation. The agreement follows Prismic's recently announced transaction with Daiichi Life, and with the closing of this deal Prismic manages approximately $25 billion of assets to support assumed liabilities. PGIM, Agam Capital Management, Willkie Farr & Gallagher and Appleby advised Prismic, while Debevoise & Plimpton served as legal counsel to Prudential.
Aging Population › Retirement Income & Annuities Capital
PRU · Capital · Positive Prudential reinsures ~$5B of Japanese whole life reserves, part of disciplined capital allocation and expanding its relationship with Prismic.
Prismic Life Holding Company · Capital · Positive Prismic assumes ~$5B of reserves, growing its assumed liabilities and assets under management to ~$25B.
Dental Corporation, or D, moves from mai to trade on SET on October 1, 2026
Dental Corporation Public Company Limited, or D, has met the criteria of the Stock Exchange of Thailand and will move from the Market for Alternative Investment, or mai, to trade on the SET in the Services industry group, Medical business sector, starting October 1, 2026, after more than 9 years listed on mai. Chief Executive Officer Pornsak Tantapakul, together with the company's board and executives, joined in congratulating the occasion. The company stated that the move to the SET reflects the organization's growth and potential, from its beginnings as a Thai family business to a listed company in the capital market, and that over the past 9 years it has used funds raised to expand its business, generating growth in revenue, net profit, and shareholders' equity. The Dental Corporation group operates a full-service dental business, covering dental hospitals, the Bangkok International Dental Hospital, or BIDH, dental centers, Smile Signature dental clinics, and Dental Planet dental clinics, as well as Dental Vision Company Limited, a subsidiary that distributes dental materials and equipment.
Aging Population › Hearing / Vision / Dental ▲Capital
Aging Population › Dental & Clear Aligners Capital
D.BK · Capital · Positive Dental Corporation moves from mai to trade on the SET, reflecting its growth in revenue, net profit, and shareholders' equity.
BLA launches 2 new annuity products, paying a first lump sum of 30% at age 60
Bangkok Life Assurance Public Company Limited, or BLA, has launched two new annuity products, BLA Pension 888 and BLA Pension & Care 888. Mr. Chone Sophonpanich, President and Chief Executive Officer, said this is the first time an annuity offers a first lump sum of 30% of the sum assured at age 60, the highest rate allowed under the Revenue Department's new criteria. After that, policyholders will receive annuity payments of 8% of the sum assured each year from age 61 to 88, and can use premiums for tax deductions of up to 300,000 baht per year. For BLA Pension & Care 888, coverage is extended to 8 critical illnesses; if diagnosed with one of these 8 critical illnesses, policyholders will receive an additional annual payment of 8% of the sum assured every year until age 88. The launch cites data from the National Statistical Office together with the Thai Health Promotion Foundation, indicating that Thais have an average life expectancy of about 78 years, and reflects the concept of Active Aging as defined by the World Health Organization. The company aims to deliver a good quality of life in four areas: physical fitness, financial readiness, mental balance, and good relationships.
Aging Population › Retirement Income & Annuities ▲Demand
BLA.BK · Technology · Positive BLA launched two new annuity products (BLA Pension 888 and BLA Pension & Care 888) with a novel 30% lump sum at 60 and 8% annual payouts, a new product development.
Nichii HD Strengthens Municipal Partnerships in Elderly Care, Investing 30 Billion Yen Over Four Years
Nichii Holdings Chairman Hiroshi Shimizu, in an interview, revealed a policy of partnering with municipalities and operators to sustain regional elderly care systems. He also indicated plans to invest 30 billion yen over four years starting this fiscal year to improve on-site response capabilities at roughly 1,900 care locations nationwide. Specific partnership measures envisioned include cost efficiency through joint purchasing of supplies and personnel support such as dispatching care assistants. Regional elderly care businesses face a harsh environment due to labor shortages and other factors, and Shimizu noted that "there are limits to what Nichii can do on its own."
Aging Population › Home Healthcare & Hospice Capital
Nichii Holdings · Capital · Positive Nichii Holdings plans to invest 30 billion yen over four years to upgrade roughly 1,900 care locations, a major capex commitment.
Nichii Holdings · Demand · Positive Partnerships with municipalities and operators, including joint purchasing and dispatching care assistants, expand its elderly care service footprint.
AtriCure Fair Value Target Rises to US$54.89 as Analysts Split on Procedure Growth
AtriCure's fair value price target has shifted from about US$51.67 to about US$54.89, reflecting modest fine tuning in analyst models rather than a wholesale reset. BTIG raised its AtriCure price target to US$55 from US$45, pointing to the new STS Quality Metric, which it thinks could support greater use of the EnCompass Clamp in U.S. surgery patients with preoperative atrial fibrillation, and noting that only about 35% of atrial fibrillation patients undergoing cardiac surgery in the U.S. currently receive a surgical ablation. BTIG models potential upside to AtriCure's U.S. Open Ablation revenue of US$10m to US$25m in 2027 and US$20m to US$55m in 2028 compared with its prior forecasts. UBS keeps a Buy rating on AtriCure alongside a revised price target of US$50 from US$55, citing business growth excluding MIS as support for what it describes as sustainable double digit top line expansion. Freedom Capital downgraded AtriCure to Hold from Buy and lifted its target to US$57 from US$43, expecting BoX-NoAF POAF data in Q2 2027 to be positive but flagging that earlier supportive data carries caveats, which it thinks reduces the margin for error if results or execution fall short of expectations. Revenue growth assumptions are broadly steady, moving from about 12.33% to about 12.35%, net profit margin expectations remain around 4.55%, future P/E has moved from about 94.5x to about 101.3x, and the discount rate is broadly unchanged, moving from about 7.52% to about 7.55%.
Aging Population › Medical Devices for the Aging Body ▲Demand
ATRC · Capital · Positive Analyst fair-value target rises to ~US$54.89 with BTIG lifting its PT to US$55 on the new STS Quality Metric supporting EnCompass Clamp use.
KTMS expects better Q4 2026 results as new branches lift utilisation rate to no less than 80%
KT Medical Service Public Company Limited, or KTMS, expects its operating performance in the fourth quarter of 2026 to improve as new branches gradually come into service. Chief Executive Officer Kanjana Pongpattanadecha told Than Hoon that branches already open have a utilisation rate of no less than 80% of total service space, reflecting demand for dialysis services that remains high. The company currently holds contracts for 11 branches and aims to open them gradually in line with its plan, with the timing of each opening depending on the government licensing process, which now takes about 120 days, up from roughly 90 days previously. This delays revenue recognition from new branches relative to plan, but it is a shift in timing rather than a loss of revenue. For the first half of 2026, the company reported revenue from the sale of goods and services of 350.63 million baht, up 7.77 million baht, or 2.27%, from the same period a year earlier, with net profit of 12.99 million baht. In the second quarter of 2026, revenue was 175.96 million baht, up 1.41% from the same period a year earlier, with net profit of 5.69 million baht.
KTMS.BK · Demand · Positive New branches opening with utilisation of at least 80% reflect high demand for dialysis services, expected to lift Q4 2026 results.
KTMS.BK · Regulation · Negative Government licensing now takes about 120 days versus 90, delaying revenue recognition from new branches relative to plan.
Trump Administration Picks 10 Drugmakers for New 340B Rebate Pilot
The Trump administration has selected 10 companies, including AbbVie, Amgen, Pfizer, and GSK, for a new pilot program that tests a rebate model for drugs purchased under a federal program benefiting uninsured and low-income patients. The 340B Rebate Model Pilot takes effect on January 1 and allows the selected manufacturers to verify and pay rebates for 21 discounted drugs purchased under the government's 340B drug pricing program, rather than offering savings upfront as under the current discount model. The participating drugmakers are AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers, GSK, Merck, Pfizer, and Teva. The Health Resources and Services Administration, the HHS unit overseeing the program, said the approach helps address compliance concerns proactively rather than relying primarily on retrospective reviews, audits, and dispute resolution processes. The pilot marks the Trump administration's second attempt to overhaul the decades-old drug discount program, after a federal judge blocked HRSA's first 340B rebate pilot following a case brought by hospital groups last year.
Aging Population › Chronic-Disease Pharma Franchises Regulation
4503.JP · Regulation · Positive Astellas is one of the selected manufacturers participating in the 340B rebate pilot program.
ABBV · Regulation · Positive AbbVie is one of 10 selected manufacturers in the new 340B rebate pilot, allowing it to pay rebates after purchase rather than upfront discounts.
AMGN · Regulation · Positive Amgen is selected for the 340B Rebate Model Pilot, shifting it to a post-purchase rebate model for discounted drugs.
AZN.LSE · Regulation · Positive AstraZeneca is selected for the 340B rebate pilot, letting it verify and pay rebates rather than give upfront discounts.
BMY · Regulation · Positive Bristol Myers is among the 10 drugmakers chosen for the administration's 340B rebate pilot taking effect January 1.
GSK.LSE · Regulation · Positive GSK is named among the 10 drugmakers in the new 340B rebate model pilot taking effect January 1.
Medtronic Raises Fiscal 2027 Guidance as Revenue Jumps 13.7%
Medtronic reported first-quarter fiscal 2027 revenue of $9.76 billion, up 13.7% from a year earlier, and raised its full-year outlook, with adjusted diluted EPS climbing 15.1% to $1.45 and GAAP EPS rising 40.7% to $1.14. Management now expects organic revenue growth of 7.25%-7.75% for fiscal 2027, up from 6.75%-7.25% previously, and lifted adjusted EPS guidance to $5.94-$6.00. The quarter included an extra selling week that added about $570 million to revenue, so the headline growth rate should not be expected to repeat. Cardiovascular delivered strong growth, while Neuroscience, Medical Surgical and Diabetes also posted high-single-digit or double-digit organic growth. At a share price of around $89-$90, the stock trades at roughly 15 times the midpoint of the adjusted EPS forecast, versus about 22 times trailing earnings, while paying a quarterly dividend of $0.72 per share, or $2.88 a year, for a yield of roughly 3.2%-3.3%. Medtronic is also expanding its Affera cardiac mapping and ablation system, investing in Pi-Cardia and Cornerstone Robotics, and has acquired Scientia Vascular and SPR Therapeutics, with a planned separation of its Diabetes business.
BrightSpring Health Services Shares Jump 4.8% After BMO Reiterates Outperform
BrightSpring Health Services shares rose 4.8% in the afternoon session after BMO Capital analyst Sean Dodge reiterated an Outperform rating and a $70 price target on the company. The reaffirmed target signals continued analyst confidence in the healthcare services provider and its long-term business outlook. The stock was trading at $60.00, up 4.8% from the previous close. BrightSpring shares are up 56.3% since the start of the year but remain 17.7% below their 52-week high of $72.91. The company's biggest recent move came two months ago, when the stock dropped 17.5% despite reporting second-quarter revenue growth of 23% year-on-year to $3.87 billion and non-GAAP profit of $0.45 per share, a sell-the-news reaction tied to valuation and margin concerns.
National Healthcare Properties to Convert Class A Common Stock into Common Stock
National Healthcare Properties, Inc. announced that all outstanding shares of its Class A common stock will automatically convert into its common stock on a one-for-one basis. The conversion will occur automatically and without any action on the part of shareholders, and immediately upon and concurrent with the conversion, no shares of Class A common stock will remain issued or outstanding. All shares of common stock will begin trading on the Nasdaq Global Market effective at 9:30 a.m. Eastern time on October 19, 2026, under a new CUSIP of 42226B600. The company said the conversion will have no effect on the economic rights of holders of Class A common stock or on its operations, and that the common stock carries the same preferences, rights, voting powers of one vote per share, restrictions, dividend and distribution limitations, qualifications and redemption terms as the Class A common stock. Cash will be paid in lieu of any fractional shares, and the conversion is being carried out pursuant to the company's charter documents as described in its Registration Statement on Form S-11 filed with the United States Securities and Exchange Commission.
AbbVie Wins FDA Approval for Juvmo, First Selective D1/D5 Parkinson's Pill
AbbVie has secured FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease, with a commercial launch targeted for October 2026. Juvmo is the first selective D1/D5 dopamine receptor agonist that can be used both as a standalone treatment and in combination with levodopa, the current standard of care for Parkinson's symptoms. The approval expands AbbVie's Parkinson's portfolio, which already includes Vyalev and Duopa, and management expects the three therapies to collectively represent a peak-sales opportunity of more than $5 billion. Neuroscience now accounts for nearly a fifth of AbbVie's overall topline and generated $6.1 billion in revenues in the first half of 2026, up 22% year over year, with the company expecting approximately $12.7 billion in neuroscience revenues for the full year. The approval could also deliver a commercial payoff from AbbVie's approximately $8.7 billion acquisition of Cerevel Therapeutics in 2024, a deal that came under pressure after emraclidine failed in two registration-enabling phase II studies in schizophrenia and prompted a $3.5 billion impairment charge. AbbVie competes in neuroscience with Biogen, which markets Leqembi with Eisai and Zurzuvae, and Johnson & Johnson, whose portfolio is anchored by Spravato and Invega Sustenna and was strengthened by last year's acquisition of Intra-Cellular Therapies, adding Caplyta.
NETSTREIT Secures $550M in New Financing, Extends Debt Maturities
NETSTREIT has secured $550 million in additional term loan commitments and amended its existing credit facilities, extending its debt maturity profile and repaying a $200 million term loan due in February 2028. The financing comprises a $100 million increase to its existing 5.5-year senior unsecured term loan, a $50 million increase to its existing 7-year term loan, and a new $400 million senior unsecured 7-year delayed draw term loan. The $100 million and $50 million incremental term loans were funded at closing, while the $400 million facility was undrawn and can be drawn through September 28, 2027. The company said the transactions leave it with no material debt maturities until early 2029 and largely address its debt capital needs through 2027.
Aging Population › Senior Housing & Healthcare REITs Capital
NTST · Capital · Positive NETSTREIT secured $550M in new term loan commitments and amended credit facilities, extending maturities and repaying a $200M term loan due 2028.
GWM25 launches ready-to-drink protein powder, targets 10 dialysis centres per year from 2027
Grace Water Med Public Company Limited, or GWM25, a leader in the development and distribution of comprehensive haemodialysis products, is preparing to launch a sachet-style ready-to-drink protein product in the fourth quarter of this year, while continuing to expand its kidney health business. Thongchai Pami, Chief Executive Officer, disclosed after presenting the company's operating results to investors at Opportunity Day that in the first six months of 2026 the company recorded total revenue of 104.68 million baht, an increase of 8.91 million baht, or 9.30%, from 95.77 million baht in the same period last year. Total liabilities fell to 78.86 million baht, while shareholders' equity rose to 64.16 million baht, bringing the debt-to-equity ratio down from 1.28 times to 1.23 times. The company currently has dialysate production capacity of approximately 240,000 gallons per month and has expanded its One-stop Service Solutions, covering everything from consultation on setting up dialysis centres, design and equipment procurement to the recruitment and training of personnel. For its second-half plan, the company is still negotiating with new partners to extend the business in several areas and will expand all products onto every online platform. The company is confident it can sustain growth in 2026, will open one dialysis centre, and will expand by 10 centres per year starting in 2027, in support of its plan to prepare for a listing on the mai stock exchange by 2028.
Edwards Lifesciences Wins FDA Approval for AUTUS Pediatric Pulmonary Valve
The US FDA has approved Edwards Lifesciences' AUTUS surgical pulmonary valve for pediatric patients with congenital heart disease. AUTUS is the first such pulmonary valve approved for children that can be expanded as a child grows, with the expansion performed through a transcatheter procedure. The approval was based on a study that found no patients had device-related complications after 30 days and no AUTUS valve reinterventions through six months. In patients with one-year follow-up, all showed consistent outcomes, with a right ventricular outflow tract mean gradient of 40 mmHg or less, less than moderate pulmonary regurgitation, and no valve reinterventions.
Aging Population › Medical Devices for the Aging Body Regulation
EW · Regulation · Positive FDA approval of the AUTUS pediatric pulmonary valve expands Edwards' transcatheter valve portfolio into a new pediatric indication.
Medtronic Wins Category I CPT Codes for Altaviva and Symplicity Spyral
Medtronic announced that the American Medical Association has approved new Category I Current Procedural Terminology codes for two of its technologies, the Altaviva implantable tibial neuromodulation device for urge urinary incontinence and the Symplicity Spyral renal denervation system for uncontrolled hypertension. The new codes, which replace existing Category III codes, take effect in January 2028. Category I codes are permanent codes assigned to procedures the AMA deems well established, widely performed across the United States, and supported by robust clinical evidence, and while they can help support physician payment and inform commercial payer coverage decisions, they do not determine coverage, reimbursement, clinical superiority, or patient access. The Altaviva device was approved by the U.S. Food and Drug Administration in September 2025 for urge urinary incontinence, a condition affecting 16 million adults in the United States, and is placed under the skin near the ankle in a minimally invasive procedure. The Symplicity Spyral system was finalized for Medicare coverage in October 2025, and Medtronic said its SPYRAL HTN global clinical program is the most comprehensive studying renal denervation, with more than 5,000 patients and experience in over 40,000 patients globally.
MDT · Regulation · Positive AMA approved permanent Category I CPT codes for Medtronic's Altaviva and Symplicity Spyral devices, supporting physician payment and payer coverage.
LTC Properties has declared a monthly common stock cash dividend of $0.19 per share for the fourth quarter of 2026, in line with its previous payout. The forward yield on the dividend stands at 5.32%. The first payment is payable Oct. 30 to shareholders of record Oct. 22, with an ex-dividend date of Oct. 22. The second is payable Nov. 30 to shareholders of record Nov. 20, ex-div Nov. 20, and the third is payable Dec. 31 to shareholders of record Dec. 23, ex-div Dec. 23.
AbbVie Draws Investor Attention as Zacks Flags Consensus Estimates
AbbVie has landed on Zacks.com's list of the most searched stocks, drawing fresh attention to the drugmaker's near-term outlook. For the current quarter, AbbVie is expected to post earnings of $3.85 per share, a change of +107% from the year-ago quarter, while the Zacks Consensus Estimate has moved -0.1% over the last 30 days. The consensus earnings estimate of $14.05 for the current fiscal year indicates a year-over-year change of +40.5%, and the next fiscal year's consensus of $16.12 points to a change of +14.8%. On the top line, the consensus sales estimate for the current quarter of $17.36 billion indicates a year-over-year change of +10%, with current and next fiscal year estimates of $67.56 billion and $73.39 billion indicating changes of +10.5% and +8.6%. In the last reported quarter, AbbVie posted revenues of $16.99 billion, up +10.2% year over year, and EPS of $3.65 versus $2.97 a year ago, beating the Zacks Consensus Estimate of $16.81 billion by +1.07% on revenue with an EPS surprise of +0.27%. The recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie, and the stock is graded C on the Zacks Value Style Score.
Aging Population › Chronic-Disease Pharma Franchises ▲Capital
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Capital
ABBV · Capital · Neutral AbbVie is the subject, drawing attention on Zacks' most-searched list with consensus estimates and a Zacks Rank #3 (Hold), a neutral analyst/valuation update.
Orchestra BioMed Surpasses Full Enrollment in BACKBEAT Pivotal Trial of AVIM Therapy
Orchestra BioMed Holdings has surpassed full enrollment in the BACKBEAT Global Pivotal Trial of AVIM Therapy, with 330 patients randomized as of September 30, 2026, exceeding the previously announced target of 316. The trial is evaluating Atrioventricular Interval Modulation Therapy in pacemaker-indicated patients with uncontrolled hypertension despite medication, and is being conducted with Medtronic, the company's strategic collaborator for the trial and, subject to regulatory approval, for commercialization of AVIM Therapy. Enrollment reached 330 patients at 81 sites across 13 countries, while the FDA-approved protocol specifies 284 evaluable randomized subjects for the primary endpoint analysis, with the 316-patient target accounting for potential loss to follow-up. Orchestra BioMed reiterated prior guidance that primary endpoint data will be submitted for late-breaking presentation consideration at a major cardiovascular conference in the second quarter of 2027, and assuming positive results, Medtronic plans to submit AVIM Therapy marketing applications to the FDA and other global regulatory agencies promptly. The trial's primary efficacy endpoint is the between-group difference in the change in 24-hour ambulatory systolic blood pressure at three-month follow-up from pre-randomization baseline, and the protocol-specified sample size provides greater than 90% statistical power to detect a between-group difference of at least 5 mmHg.
Aging Population › Medical Devices for the Aging Body ▲Technology
OBIO · Technology · Positive Orchestra BioMed surpassed full enrollment (330 patients) in the BACKBEAT pivotal trial of its AVIM Therapy, advancing toward primary endpoint data in Q2 2027.
MDT · Technology · Positive Medtronic is the strategic collaborator on the BACKBEAT trial of AVIM Therapy and plans to submit marketing applications if results are positive.
SpyGlass Pharma Acquires Advanced Vision Science for $13 Million
SpyGlass Pharma, Inc. announced today it has acquired all outstanding shares of common stock of Advanced Vision Science, Inc., an ophthalmic medical device company and manufacturer of intraocular lenses and lens materials, for approximately $13 million in cash. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd. and is the current supplier of the intraocular lens used in SpyGlass Pharma's two Phase 3 registrational trials evaluating the BIM-IOL System. The acquisition secures scalable commercial intraocular lens manufacturing capacity for SpyGlass Pharma's lead product candidate and accelerates its pathway to adding premium lens options into its intraocular-lens-based drug delivery system. Under the agreement, AVS will be the exclusive manufacturer and supplier of several types of intraocular lenses to Santen for commercialization in Japan, and will continue to license its glistening-free hydrophobic acrylic lens material to Bausch + Lomb for use in the enVista intraocular lens line and manufacture products for other global intraocular lens companies. SpyGlass Pharma said it intends to continue supporting AVS customers and licensees utilizing their proprietary intraocular lens material technology, such as Santen, Bausch + Lomb, and other global intraocular lens companies.
SGP · Supply · Positive SpyGlass acquires AVS, securing scalable commercial intraocular lens manufacturing capacity for its lead BIM-IOL product candidate.
Advanced Vision Science, Inc. · Capital · Positive Advanced Vision Science is acquired by SpyGlass Pharma for approximately $13 million in cash.
4536.JP · · Neutral Santen sold its AVS subsidiary for ~$13M but retains AVS as exclusive manufacturer/supplier of intraocular lenses for commercialization in Japan.
Neuromod Appoints Joe Ghiz as Chief Commercial Officer, Shannon Basham as VP of Channel Development
Neuromod Devices has announced the appointment of Joe Ghiz as Chief Commercial Officer and Shannon Basham as VP of Channel Development. Ghiz joins Neuromod's senior management team and will lead the company's global commercial function as it continues to strengthen its position as the category creator in tinnitus care, with CEO Dr. Ross O'Neill citing robust clinical evidence, global regulatory approval, and broad commercial adoption as positioning the company for rapid scaling to address the needs of 740 million tinnitus sufferers worldwide. Ghiz joins from Align Technology, the company behind Invisalign, where he helped create and scale the clear aligner category and built a $10 billion company, and previously spent over a decade at Johnson & Johnson Vision Care in leadership roles spanning sales, marketing, and business development. Basham brings more than 20 years of experience in the hearing care industry, having most recently served as Senior Director of Audiology for Sonova Group in the United States of America, where she was the market-facing head of audiology for the Phonak and Unitron wholesale businesses. The appointments support Neuromod's goal of positioning its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire, as a new standard of care in ENT and audiology practices.
United StatesBrazilChinaIndiaJapanSouth KoreaPuerto RicoSlovakia+2
Chronic-Disease Pharma Franchises▲6
Lilly's oral GLP-1 Foundayo linked to 57% cut in predicted type 2 diabetes risk
Eli Lilly and Company said post-hoc analyses of the ATTAIN-1 trial showed its oral GLP-1 Foundayo, or orforglipron, was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem. At 72 weeks, participants taking Foundayo 5.5 mg, 9 mg and 17.2 mg showed estimated reductions in predicted type 2 diabetes risk versus placebo of 45.0%, 50.0% and 57.0%, respectively, while those taking Foundayo 17.2 mg also showed an estimated 18.0% reduction in predicted cardiovascular disease risk versus placebo. The findings were published in Diabetes, Obesity and Metabolism. Thomas Seck, M.D., senior vice president of product development at Lilly Cardiometabolic Health, said the analyses showed Foundayo was associated with a lower predicted long-term risk of both conditions in addition to meaningful weight loss, and that treating obesity and reducing downstream consequences can meaningfully lower healthcare costs. ATTAIN-1 was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial that randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan. Foundayo is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, and orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018.
Johnson & Johnson Moat Holds as Icotyde Estimate Raised to $4.5 Billion
Johnson & Johnson's economic moat rests on its ability to keep producing drugs rather than on any single drug, with the company's medical device business adding long-term hospital contracts that make switching suppliers closer to a retraining exercise than a purchasing decision. The company is worth about $638 billion and turns 29.19% of its $97.93 billion in revenue into operating profit, while return on equity reaches 25.74% and free cash flow ran to $16.89 billion over the past twelve months. Revenue grew 6.60% last quarter, and the balance sheet carries $49.04 billion of debt. On September 29, Bank of America raised its peak sales estimate for the oral psoriasis treatment Icotyde to $4.5 billion, from $2.4 billion previously, a test of whether the pipeline can replace revenue lost to patent expiries. Johnson & Johnson has spent years managing talc claims, and the shares now trade near 31 times trailing earnings but only about 21 times what analysts forecast for next year, on a yield of 2.02%.
Novo's Ozempic Cuts Cardiovascular Risk More Than Lilly's Mounjaro in Real-World Study
Novo Nordisk said new real-world data from its COMPETE SWITCH Cardiovascular study found that type II diabetes patients who increased their Ozempic dose had a lower observed risk of major adverse cardiovascular events than those who switched to Eli Lilly's Mounjaro. In the study, 67.2% of patients remained on Ozempic 1 mg within 365 days, 29.2% increased their dose to 2 mg and 3.6% switched to Mounjaro; by 720 days, 57.4% remained on semaglutide 1 mg, 36.9% had escalated to 2 mg and 5.7% had switched to Mounjaro. After adjustment for between-group differences, patients who increased their dose to Ozempic 2 mg had a statistically significant 6% lower risk of MACE than those who switched to Mounjaro, including doses of up to 15 mg, with MACE defined as all-cause death, heart attack and stroke. Novo cautioned that the study showed an association, not proof, that Ozempic 2 mg directly reduces cardiovascular risk more than Mounjaro, and that safety outcomes were not evaluated. Year to date, Novo shares have lost 22.2% against the industry's 14.9% growth.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Aging Population › Chronic-Disease Pharma Franchises ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
NVO · Technology · Positive Novo's own COMPETE SWITCH study found escalating to Ozempic 2 mg was associated with a statistically significant 6% lower MACE risk than switching to Mounjaro.
LLY · Competition · Negative Real-world COMPETE SWITCH data show patients on Ozempic 2 mg had a 6% lower MACE risk than those who switched to Lilly's Mounjaro, a competitive blow to Mounjaro.
Smith+Nephew Launches EVOS PELVIC Plating System for Pelvic and Acetabular Fractures
Smith+Nephew has launched the EVOS PELVIC Plating System, expanding its EVOS trauma platform into pelvic and acetabular fracture management. The system is designed to address a broad range of pelvic and acetabular fracture patterns, with pre-contoured options for the posterior wall, quadrilateral surface and pubic symphysis, along with locking and non-locking utility plates, and a dedicated cannulated screw platform and specialized instruments for fracture exposure, reduction and implant placement. The company said the integrated design allows surgeons to obtain and fine-tune fracture reduction before maintaining fixation through the healing process, which it believes could make complex pelvic procedures more efficient and reproducible. The EVOS PELVIC System is currently available in the United States, while timing and availability in other markets will vary. According to Data Insights Reports, the global pelvic trauma management market was valued at $2.81 billion in 2025 and is projected to reach $4.79 billion by 2034, expanding at a 6.1% CAGR. Smith+Nephew, which has a market capitalization of $11.37 billion, in August announced the launch of the FLOW FLEXTEND COBLATION Wand, a new RF resection technology for complex hip procedures.
Merck Q2 Revenue Rises 5.1% to $16.61 Billion, Beats Estimates
Merck reported second-quarter revenues of $16.61 billion, up 5.1% year on year and 2.1% above analysts' expectations, as the nine branded pharmaceuticals stocks tracked by the report collectively beat consensus revenue estimates by 6.6%. The company beat analysts' EPS estimates but missed analysts' full-year EPS guidance estimates, and its stock is up 16.2% since reporting, trading at $148.50. Among peers, Corcept Therapeutics posted the group's best quarter with revenues of $256.1 million, up 31.7% year on year and 21.6% above expectations, while Zoetis delivered the weakest performance with revenues of $2.47 billion, flat year on year and 1.5% below expectations. Collegium Pharmaceutical reported revenues of $199.9 million, up 6.3% year on year but 0.7% below expectations, and Pfizer reported revenues of $15.03 billion, up 2.6% year on year and 4.4% above expectations. As a group, share prices of the tracked companies have held steady, up 2.1% on average since the latest earnings results.
Eli Lilly Shares Rise After Foundayo Shows More Weight Loss
Eli Lilly shares edged 1% higher in morning trading Tuesday after new data showed its oral Foundayo treatment produced greater weight and blood-sugar reductions than oral semaglutide at higher doses. The analysis examined 17.2 mg of Foundayo, or orforglipron, in adults with type 2 diabetes, and at week 52 patients receiving the Lilly drug recorded 1.5% more body-weight reduction than those taking 25 mg of oral semaglutide. The blood-sugar measure A1C also moved in Lilly's favor, with the analysis showing a further 0.3% reduction compared with the semaglutide group. The findings were presented during the European Association for the Study of Diabetes meeting in Milan, where EASD materials listed additional studies involving the treatment. Lilly has been developing Foundayo across its diabetes program as competition in oral GLP-1 medicines expands, though the comparison comes from separate studies rather than a direct head-to-head trial.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Aging Population › Chronic-Disease Pharma Franchises ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
LLY · Technology · Positive New data showed Lilly's oral Foundayo produced greater weight and blood-sugar reductions than oral semaglutide at higher doses.
Lilly Says Higher-Dose Zepbound Widened Weight-Loss Lead Over Wegovy
Eli Lilly says higher doses of Zepbound may have widened its weight-loss advantage over Novo Nordisk's Wegovy. A new indirect analysis found that patients receiving Zepbound 15 mg and 10 mg had 4.5 percentage points and 3.2 percentage points more weight loss, respectively, over 72 weeks than patients taking high-dose Wegovy. According to Lilly, patients receiving Zepbound 15 mg were three times more likely to lose at least 20% of their body weight compared with those receiving Wegovy HD, and the difference was even more pronounced among people reaching larger weight-loss goals. Discontinuation rates because of adverse events were comparable across the Zepbound 10 mg, Zepbound 15 mg and Wegovy HD groups. Lilly cautioned that the results did not come from a direct head-to-head trial, comparing data from its Phase 3 SURMOUNT-1 study with Novo Nordisk's STEP UP studies. Novo shares were down about 1.3% in Tuesday premarket trading, while Lilly was up roughly 0.4%.
AbbVie Wins FDA Approval for Juvmo Parkinson's Treatment
AbbVie secured FDA approval for Juvmo, a once-daily Parkinson's treatment, though its shares slipped nearly 0.8% to $264.29. Juvmo works through D1/D5 dopamine receptors, a different target from older dopamine agonists. In the TEMPO-3 trial, patients taking it alongside levodopa gained 1.7 hours a day with symptoms controlled and no troublesome involuntary movement, compared with 0.6 hours for those given a placebo. AbbVie expects U.S. availability in October but has not disclosed Juvmo's price or a sales forecast, and nausea, dizziness and hallucinations are among the treatment concerns physicians must weigh. At $264.29, the stock sits 19.43% above its $221.28 GF Value estimate.
Integer Holdings to Be Acquired by KKR Affiliates for $127 Per Share in Cash
Integer Holdings Corporation has entered into a definitive agreement to be acquired by affiliates of Kohlberg Kravis Roberts & Co. L.P., with each eligible share convertible into the right to receive $127 in cash at closing. The transaction, announced on Aug. 2, 2026, is not subject to a financing condition, and the buyer has obtained equity and debt financing commitments; completion remains subject to customary conditions, including approval by holders of a majority of outstanding shares and required regulatory clearances. The agreement provides for a $307 million parent termination fee in certain circumstances involving a buyer breach or failure to complete the transaction when required, and if completed, Integer Holdings would become a wholly owned subsidiary of the buyer and its shares would be delisted from the NYSE. The medical device outsourcing manufacturer, which has a market capitalization of $4.3 billion, reported mixed second-quarter 2026 results, with revenues declining 2.6% year over year to $464.1 million and adjusted earnings per share rising 3.2%. Cardio & Vascular sales fell 2% to $280.3 million on lower-than-expected adoption of two new electrophysiology products, while Cardiac Rhythm Management & Neuromodulation sales rose 1% to $173.7 million, and gross margin declined to 24.3% from 27.1% a year earlier. The Zacks Consensus Estimate for third-quarter 2026 revenues is $457.3 million, indicating a 2.2% decline from the year-ago quarter, with earnings pegged at $1.65 per share, implying a 7.8% decline.
Fresenius Medical Care Reshapes China Portfolio, Exits Peritoneal Dialysis
Fresenius Medical Care AG & Co. FMS is refining its China commercial strategy to prioritize advanced in-center dialysis and critical-care technologies while discontinuing local production and sales of the 4008A hemodialysis system and exiting its China peritoneal dialysis business. China contributes approximately 6-7% of the company's Care Enablement operating segment revenues, and the company will emphasize the high-volume hemodiafiltration-enabled 5008S CAREsystem, multiFiltratePRO and other advanced dialysis technologies, supported by its local manufacturing footprint and China Design Center. The portfolio actions are expected to result in approximately €110 million of one-time costs, primarily impairment charges, scrappage and termination costs, recognized as a special item in the third quarter of 2026, and FMS does not expect the changes to significantly affect the future revenue outlook for its China Care Enablement business. The company also appointed Rex Liu as market general manager, and Joe Turk, CEO of the Care Enablement operating segment, said the refined portfolio and strategy will strengthen its ability to compete and grow in China. FMS stock has gained 1.1% since the announcement on Friday and has a market capitalization of $12.19 billion.
Aging Population › Dialysis & Renal Care ▼Competition
FME.XETRA · Capital · Neutral Fresenius Medical Care exits China peritoneal dialysis and discontinues 4008A production, taking ~€110M one-time impairment/termination costs as a special item.
BofA Lifts J&J Target to $278, Sees Q3 EPS 12% Below Street
BofA Securities raised its price target on Johnson & Johnson to $278 from $263 while keeping a Neutral rating, lifting its forecasts for Icotyde and updating its model for recent in-process research and development charges. The new target applies 22x BofA's 2027 earnings estimate excluding those charges, up from 20.33x, which the firm tied to a sector re-rating for defensive stocks. For the third quarter, BofA expects sales of $25.5 billion, in line with consensus, and EPS of $2.53, 12% below the Street, with J&J having disclosed $0.64 of in-process R&D dilution for 2026, mostly falling in the third quarter. BofA models 6% revenue growth, with Pharma up 7% and MedTech up 4%, and points to IQVIA data showing four-week rolling prescriptions up 50% year over year for Tremfya in inflammatory bowel disease and 60% for Caplyta in major depressive disorder. Separately, J&J is reportedly in talks with Apollo Global Management over a potential sale of its orthopedics unit, which could be valued at nearly $20 billion.
Aging Population › Chronic-Disease Pharma Franchises ▲Capital
Aging Population › Medical Devices for the Aging Body Capital
JNJ · Capital · Positive BofA lifted its J&J price target to $278 on a defensive-sector re-rating and higher Icotyde forecasts.
BAC · Capital · Neutral BofA raised its J&J price target to $278 and updated its model, but the article gives no clear positive/negative read on BofA itself.
APO · Capital · Neutral Reportedly in talks with J&J over a potential ~$20B purchase of its orthopedics unit; deal is only exploratory.
Marsh Launches Archer to Build Reinsurance Businesses for Insurers
Marsh & McLennan Companies has launched Archer by Marsh, a new service that helps life and annuity insurers, asset managers and capital providers create and run reinsurance businesses globally. Archer takes Marsh beyond traditional advisory work by supporting the full process, from product, asset and capital decisions to regulatory approval, setup and ongoing operations, with clients able to use Marsh's shared infrastructure while keeping ownership and strategic control. The offering combines actuarial, capital, risk, reinsurance, insurance management and regulatory expertise and can support standalone reinsurance vehicles, special purpose reinsurers and dedicated cells, and Marsh also formed Bermuda-based Mangrove ISAC Life Re to facilitate sidecar and affiliate reinsurance solutions. Marsh brings scale to the offering, reporting about $27 billion in annual revenues, more than 95,000 employees and operations across 130 countries. The move is likely to broaden Marsh's revenue mix beyond brokerage and consulting by adding recurring, service-based income from operating reinsurance vehicles after launch, and could create a more durable revenue stream tied to the ongoing operation of reinsurance businesses if adoption grows.
Aging Population › Retirement Income & Annuities ▲Supply
MRSH · Capital · Positive Marsh launched Archer by Marsh to build and operate reinsurance businesses, broadening its revenue mix with recurring service-based income.
Mangrove ISAC Life Re · Capital · Positive Marsh formed Bermuda-based Mangrove ISAC Life Re to facilitate sidecar and affiliate reinsurance solutions.
Japan poll shows 70% support using AI and robots in healthcare to address staffing crisis
Japan's Ministry of Health, Labour and Welfare revealed the findings of its annual white paper, showing that more than 70% of Japanese people have a positive attitude toward the use of advanced technologies such as artificial intelligence and robots in the medical and nursing care sectors. The online opinion survey found that 72.4% agreed or somewhat agreed with using AI to help doctors diagnose diseases, and 73.7% supported the use of robots to facilitate communication between caregivers and care recipients. At the same time, 74.5% said they felt or somewhat felt anxious about the shortage of healthcare workers, and 81.3% expressed similar concern about elderly care. The study underscores the importance of improving efficiency and raising productivity by adopting technology around 2040, when Japan's population aged 65 and over is expected to peak, amid a worsening shortage of doctors, nurses, and caregivers. The survey was conducted in January and February among people living in Japan aged 20 to 74, and received 3,000 complete responses.
Krungsri stays bullish on hospital sector, picks BDMS and PR9 as top stocks
Krungsri Securities Public Company Limited said flooding in Bangkok and its surrounding provinces has affected travel for patients and staff, particularly outpatients, or OPD, and procedures that can be postponed, or elective cases. However, the hospitals under coverage are still operating normally and have no flooding inside their facilities, with the impact on 2026 revenue and profit forecasts remaining limited. Most of the hospitals under coverage derive about 50% of total revenue from OPD, and patients who postponed appointments are expected to gradually return for services once the situation eases. The research team maintains a bullish view on the hospital sector, selecting BDMS as a top pick with a target price of 25 baht and PR9 with a target price of 24 baht. Meanwhile, BCH, with a target price of 12 baht, remains attractive on upside if social security treatment fees are raised.
Kasikorn Securities says delay in SSO board election won't affect service rate adjustment, recommends buying BCH and RJH
Kasikorn Securities assesses that the two-week delay in the election of the Social Security Office board is unlikely to affect the approval of adjustments to medical treatment service rates, which are currently under review by the subcommittee considering medical treatment rate levels. The new SSO board is expected to begin work within November, later than the previously expected October, and the board will be the one to approve the subcommittee's meeting results and set the effective date of the new service rates. Currently, the subcommittee is scheduled to hold its third meeting on October 5, at which a conclusion on the rate adjustment is expected. If no conclusion is reached, a fourth meeting may be needed on October 24, which must be held before that date because it is when the subcommittee's term expires. The research team maintains a neutral view on the hospital sector, with PR9 as its top pick, and holds a positive view that the subcommittee will consider raising the flat-rate payment by 5%, assuming the flat-rate adjustment takes effect from 2027 onward in its profit forecasts for the three social security hospital stocks under coverage. It recommends buying BCH with a target price of 12.50 baht and RJH with a target price of 17.20 baht, and recommends holding CHG with a target price of 1.69 baht. However, if the Social Security Office does not raise service rates at all, the DCF value would fall 5% for BCH to 11.9 baht, fall 4% for RJH to 16.50 baht, and fall 4% for CHG to 1.69 baht.
Lilly Captures 70% of 700,000 New Medicare GLP-1 Patients
Eli Lilly CEO David Ricks said about 700,000 new seniors have started GLP-1 treatment since Medicare began covering obesity drugs in July, with roughly 70% using Lilly medicines. The temporary Medicare Bridge program lets eligible beneficiaries obtain obesity treatments for a $50 monthly co-pay, giving Zepbound and Foundayo access to a population that previously faced limited Medicare coverage. The early uptake matters because Zepbound generated $9.09 billion in revenue in the first half of 2026, up 60% year over year, while Mounjaro generated $18.61 billion, up 106%, with the two drugs together representing 65% of Lilly's total revenue in the period. Ricks said Zepbound remains popular among patients with higher body weight and more complications, while one-third of new oral GLP-1 patients are taking Foundayo, which Reuters reported had captured more than 30% of new U.S. oral obesity-drug patients. Medicare's Bridge program also covers Novo Nordisk's Wegovy and runs through December 2027, and Lilly has said higher volumes of Mounjaro and Zepbound have come with lower realized prices.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
LLY · Demand · Positive Medicare Bridge coverage drove ~700,000 new seniors to GLP-1s, with roughly 70% using Lilly medicines like Zepbound and Foundayo
NVO · Demand · Neutral Medicare Bridge program also covers Novo Nordisk's Wegovy, but the article gives no specific uptake figures for Novo
Lennar Opens Three New Communities in Pennsylvania, Alabama and California
Lennar has opened three new residential communities across Pennsylvania, Alabama and California. In Hatfield, Pennsylvania, the builder launched Venue at Leaf Creek, an active adult community with amenities tailored to buyers aged 55 and over. Near Huntsville, Alabama, Lennar introduced Cherokee Bend, offering new single family homes across multiple floor plans. In San Juan Capistrano, California, the company launched The Farm, a residential project adding more new construction options in the state. The three launches target different price points and life stages, fitting Lennar's asset-light, volume-focused model of keeping sales flowing across a wide mix of communities even when conditions are tougher.
Aging Population › Senior Housing & Healthcare REITs Competition
LEN · Demand · Positive Lennar opened three new residential communities across Pennsylvania, Alabama and California, expanding its home offerings to different price points and life stages.
